Skip to main content
. 2022 Jan 12;12:801897. doi: 10.3389/fimmu.2021.801897

Figure 1.

Figure 1

Serum concentrations of cf-nDNA and cf-mtDNA in immunosuppressive therapy-naïve patients with AAV. Concentrations of cf-nDNA in HC and patients with EGPA, MPA, and GPA before immunosuppressive therapy measured by qPCR using primer sets for the 115-bp ALU repeats. (B) Concentrations of cf-mtDNA in HC and patients with EGPA, MPA, and GPA before immunosuppressive therapy measured by qPCR using primer sets for 79-bp gene fragment of mitochondrial 16s-RNA. (C) Serum DNase1 activity before treatment measured by fluorescence spectrophotometry. One unit of DNase1 was defined as the amount of enzyme that cleaved 1.0 µmol of DNA probe per minute. EGPA: n=10, MAP: n=13, GPA: n=12, HC: n=10, *P < 0.05, **P < 0.01, ***P < 0.001, Mann–Whitney U test.